One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Axcella Health  logo
Axcella Health AXLA
report update icon

Quarterly report 2023-Q2
added 05-16-2026

Axcella Health Financial Statements 2022-2011 | AXLA

Annual Financial Statements Axcella Health

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

25 M 65.2 M 173 M 80.5 M - - - - - - - -

Shares

54.4 M 38.1 M 31.7 M 16.6 M 4.55 M - - - - - - -

Historical Prices

0.46 1.71 5.44 4.84 - - - - - - - -

Net Income

-81.2 M -64.6 M -56.5 M -59 M -36.1 M -30.9 M - - - - - -

Operating Income

-77 M -61.8 M -53.8 M -57.4 M -33.9 M - - - - - - -

Interest Expense

3.02 M 2.92 M 10 K 3.4 M 2.78 M - - - - - - -

EBITDA

-76.6 M -61.6 M -53.4 M -56.8 M -32.8 M -27.6 M - - - - - -

Operating Expenses

77 M 61.8 M 53.8 M 57.4 M 33.9 M - - - - - - -

General and Administrative Expenses

15.8 M 18.7 M 16.8 M 15.8 M 8.41 M 6 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Axcella Health

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

73.7 M 73.7 M 73.7 M 52.6 M 52.6 M 41.4 M 39.2 M 38.2 M 37.7 M 37.7 M 37.6 M 36.9 M 29.2 M 23.2 M 23.2 M 23.1 M 15.2 M 4.78 M 4.77 M 4.77 M 4.41 M 4.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-3.41 M -3.98 M - -17.8 M -21.3 M -19 M - -15.6 M -15.9 M -15.2 M - -12.4 M -13.9 M -15 M - -17.3 M -14.4 M -11.6 M - -8.78 M -9.42 M -8.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - 257 K - - - 390 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.54 M -4.18 M - -17.1 M -20.6 M -18.3 M - -14.9 M -15.2 M -14.5 M - -11.7 M -13.2 M -14.5 M - -17 M -14.1 M -11 M - -8.23 M -8.91 M -7.59 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-2 K 67 K - -43 K - -27 K - - -5 K - - -712 K -708 K 802 K - -307 K -376 K -542 K - -550 K -515 K -509 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-3.54 M -4.17 M - -16.8 M -20.5 M -18.3 M - -14.7 M -15.1 M -14.4 M - -11.4 M -12.9 M -14.3 M - -16.5 M -13.7 M -10.8 M - -7.38 M -8.28 M -7.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

3.54 M 4.18 M - 17.1 M 20.6 M 18.3 M - 14.9 M 15.2 M 14.5 M - 11.7 M 13.2 M 14.5 M - 17 M 14.1 M 11 M - 8.23 M 8.91 M 7.59 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.32 M 2.75 M - 3.78 M 3.75 M 4.79 M - 4.77 M 4.95 M 4.26 M - 4.18 M 4.62 M 4.12 M - 4.84 M 4.73 M 3.47 M - 2.09 M 2.9 M 2.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Axcella Health AXLA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Axcella Health plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.61 -8.44 % $ 65.1 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Seer Seer
SEER
$ 1.62 -3.57 % $ 89.7 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Shattuck Labs Shattuck Labs
STTK
$ 4.86 -2.71 % $ 338 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.78 0.15 % $ 2.8 B britainBritain
Stoke Therapeutics Stoke Therapeutics
STOK
$ 27.16 -1.98 % $ 1.61 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 10.08 -5.0 % $ 85.7 M usaUSA
Soligenix Soligenix
SNGX
$ 0.32 -6.35 % $ 1.66 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 42.54 -1.0 % $ 48.7 B israelIsrael
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.99 -3.55 % $ 2.03 M chinaChina
Spruce Biosciences Spruce Biosciences
SPRB
$ 46.36 -6.04 % $ 35.5 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 20.9 -0.9 % $ 33 B japanJapan
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 28.77 4.15 % $ 1.62 B usaUSA
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Savara Savara
SVRA
$ 4.92 -2.57 % $ 1.09 B usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
$ 64.27 1.4 % $ 9.28 B usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 14.92 -2.55 % $ 2.01 B usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
- - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
- 0.38 % $ 12.9 M israelIsrael
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
- 2.07 % $ 34.4 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
- -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
- - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 972.42 1.05 % $ 59.6 B niderlandNiderland
XBiotech XBiotech
XBIT
$ 1.97 3.2 % $ 60.1 M usaUSA
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.76 -2.09 % $ 2.99 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 30.86 2.22 % $ 3.14 B usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain